. 2015 Sep 2;309(9):F764–F769. doi: 10.1152/ajprenal.00201.2015

Table 1.

SPR4 prevents GBCA-induced hyperphosphatemia and hypercalcemia in Hyp mice

	Hyp Mice Serum Chemistry (mg/dl; n = 6)
	Vehicle	Gadobenate	Gadobenate+SPR4
Serum PO⁴⁺	4.36 ± 0.50^b	5.95 ± 0.48^{a c}	4.12 ± 0.57^b
Serum Ca²⁺	9.73 ± 0.33^b	11.64 ± 1.13^{a c}	9.70 ± 0.35^b
		Hyp Mice (mRNA Fold-Expression; n = 6)
Tissue	Gene	Vehicle vs. gadobenate	Vehicle vs. gadobenate+SPR4
Kidney	NPT2A	1.84 ± 0.51^*	NS
	NPT2C	1.92 ± 0.43^*	NS
	1-α-Hydroxylase	NS	NS
Bone	SOST (Sclerostin)	−2.86 ± 0.19^*	NS

Values are means ± SD. GBCA, gadolinium-based contrast agents. Serum chemistry measurements are for male mice with increased ASARM peptide (Hyp; n = 6; 5 wk of age) infused with vehicle, gadobenate, or gadobenate+SPR4 peptide for 3 days. a, b, and c Significant difference (P < 0.05) for vehicle (a), gadobenate (b), and gadobenate+SPR4 peptide (c), respectively. “Fold” mRNA expression levels (quantitative RT/PCR) for vehicle vs. gadobenate and vehicle vs. gadobenate+SPR4 peptide” are also shown for both bone and kidney. Expression analyses were carried out as described previously, PCR efficiencies were calculated for each primer set, and transferrin was used as a housekeeping gene (16, 18). Significant difference was calculated using a Wilcoxon signed rank test (theoretical median = 1). NPT2A and C are renal Na-dependent phosphate cotransporters. The pharmaceutical name for gadobenate is MultiHance. NS, not significant.

Significant difference (P < 0.05) vehicle.